Skip to main content
Contact Us
Subscribe
E-Edition
32°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by aTyr Pharma, Inc.
aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
December 10, 2024
From
aTyr Pharma, Inc.
Via
GlobeNewswire
Tickers
ATYR
aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis
December 09, 2024
From
aTyr Pharma, Inc.
Via
GlobeNewswire
Tickers
ATYR
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
November 15, 2024
From
aTyr Pharma, Inc.
Via
GlobeNewswire
Tickers
ATYR
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
November 07, 2024
From
aTyr Pharma, Inc.
Via
GlobeNewswire
Tickers
ATYR
aTyr Pharma to Present at Upcoming Investor Conferences
October 31, 2024
From
aTyr Pharma, Inc.
Via
GlobeNewswire
Tickers
ATYR
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
October 08, 2024
From
aTyr Pharma, Inc.
Via
GlobeNewswire
Tickers
ATYR
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
October 02, 2024
From
aTyr Pharma, Inc.
Via
GlobeNewswire
Tickers
ATYR
aTyr Pharma to Participate in September Investor Conferences
August 21, 2024
From
aTyr Pharma, Inc.
Via
GlobeNewswire
Tickers
ATYR
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
August 13, 2024
From
aTyr Pharma, Inc.
Via
GlobeNewswire
Tickers
ATYR
aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations
August 06, 2024
From
aTyr Pharma, Inc.
Via
GlobeNewswire
Tickers
ATYR
aTyr Pharma Announces Research Study with Stanford Medicine
July 30, 2024
From
aTyr Pharma, Inc.
Via
GlobeNewswire
Tickers
ATYR
aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
July 22, 2024
From
aTyr Pharma, Inc.
Via
GlobeNewswire
Tickers
ATYR
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
June 03, 2024
From
aTyr Pharma, Inc.
Via
GlobeNewswire
Tickers
LIFE
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 24, 2024
From
aTyr Pharma, Inc.
Via
GlobeNewswire
Tickers
LIFE
aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
May 15, 2024
From
aTyr Pharma, Inc.
Via
GlobeNewswire
Tickers
LIFE
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
May 14, 2024
From
aTyr Pharma, Inc.
Via
GlobeNewswire
Tickers
LIFE
aTyr Pharma to Present at Upcoming Investor Conferences
May 06, 2024
From
aTyr Pharma, Inc.
Via
GlobeNewswire
Tickers
LIFE
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
May 02, 2024
From
aTyr Pharma, Inc.
Via
GlobeNewswire
Tickers
LIFE
aTyr Pharma to Participate in April Investor Conferences
April 01, 2024
From
aTyr Pharma, Inc.
Via
GlobeNewswire
Tickers
LIFE
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
March 14, 2024
From
aTyr Pharma, Inc.
Via
GlobeNewswire
Tickers
LIFE
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
February 28, 2024
From
aTyr Pharma, Inc.
Via
GlobeNewswire
Tickers
LIFE
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
February 21, 2024
From
aTyr Pharma, Inc.
Via
GlobeNewswire
Tickers
LIFE
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
January 29, 2024
From
aTyr Pharma, Inc.
Via
GlobeNewswire
Tickers
LIFE
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
January 18, 2024
From
aTyr Pharma, Inc.
Via
GlobeNewswire
Tickers
LIFE
aTyr Pharma to Present at November Investor Conferences
November 01, 2023
From
aTyr Pharma, Inc.
Via
GlobeNewswire
Tickers
LIFE
aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILD
October 31, 2023
From
aTyr Pharma, Inc.
Via
GlobeNewswire
Tickers
LIFE
aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
September 11, 2023
From
aTyr Pharma, Inc.
Via
GlobeNewswire
Tickers
LIFE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.